Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Summary

There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.

Timeline

Start

2016-03-17

Primary completion

2016-08-26

Completion

2016-08-26

Drugs

Indications